The goal of this study is to evaluate and analyze the effects of edaravone (EDV) dexborneol on neurological function and serum inflammatory factor levels among patients with acute anterior circulation big artery blockage stroke. A total of 142 patients with acute anterior circulation large vessel occlusion (LVO) were randomly allocated to the study group (69 patients) or the control group (73 patients). In the study group, patients were treated with 37.5 mg EDV dexborneol twice a day for 10-14 days, based on the control group. The primary efficacy outcome was the National Institutes of Health Stroke Scale score change from baseline to 90 days and the proportion of modified Rankin Scale (mRS)score ≤1 at 90 days after randomization. The secondary outcome included the decrease in inflammatory factors at 14 days. The primary safety outcome was the incidence of hemorrhagic transformation assessed according to Heidelberg bleeding classification within 7 days. A higher percentage of patients with HIHSS score ≤5 at 90 days in the EDV dexcamphorol group was observed than in the control group (75.36% vs 64.38%; P = 0.015). A higher percentage of patients with mRS score ≤1 at 90 days in the EDV dexcamphorol group was observed than in the control group (63.77% vs 50.68%; P = 0.012). After treatment, the levels of IL-6 and hs-CRP were significantly lower following treatment and compared to the control group (P < 0.05). In patients receiving the EDV dexborneol group, a significantly decreased risk of radiographic intracranial hemorrhage was found compared with the control group (20.29% vs 39.73%; P = 0.0006). In conclusion, EDV dexborneol can improve the clinical outcomes of patients with acute anterior circulation LVO stroke, which can be used as an effective supplement to thrombectomy therapy.

中文翻译：

---

依达拉奉右冰片对急性前循环大血管闭塞性脑卒中患者神经功能及血清炎症因子水平的影响

本研究的目的是评估和分析依达拉奉（EDV）右冰片对急性前循环大动脉阻塞性卒中患者神经功能和血清炎症因子水平的影响。共有 142 例急性前循环大血管闭塞（LVO）患者被随机分为研究组（69 例）和对照组（73 例）。在研究组中，患者在对照组的基础上接受 37.5 mg EDV 右冰片治疗，每天两次，持续 10-14 天。主要疗效结果是美国国立卫生研究院卒中量表评分从基线到 90 天的变化以及随机化后 90 天时改良 Rankin 量表 (mRS) 评分≤1 的比例。次要结果包括 14 天时炎症因子的减少。主要安全性结局是根据海德堡出血分类评估的 7 天内出血转化的发生率。EDV 右樟脑组 90 天时 HIHSS 评分≤5 的患者比例高于对照组（75.36% vs 64.38%；P = 0.015）。EDV 右樟脑组 90 天时 mRS 评分≤1 的患者比例高于对照组（63.77% vs 50.68%；P = 0.012）。治疗后，治疗后IL-6、hs-CRP水平均显着低于对照组（P < 0.05）。与对照组相比，接受 EDV 右冰片组的患者放射学颅内出血风险显着降低（20.29% vs 39.73%；P = 0.0006）。总之，EDV右冰片可以改善急性前循环LVO脑卒中患者的临床结局，可作为取栓治疗的有效补充。